Patent ID: 7556809

Claim:
An immunogenic composition comprising an autologous VEGF-A polypeptide impaired for receptor activation identified as the amino acid sequence set forth in SEQ ID NO: 21 or fragments thereof identified as the amino acid sequence set forth in SEQ ID NO: 27 to SEQ ID NO: 36 and SEQ ID NO: 77 to SEQ ID NO: 86; and at least one of the molecules described in: a) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196; b) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or fused to p64K protein of Neisseria meningitides ; c) VEGFR2 polypeptide fragments identified as the amino acid sequence set forth in SEQ ID NO: 137 to SEQ ID NO: 146 and SEQ ID NO: 187 to SEQ ID NO: 196, said composition being mixed with or noncovalently bound to very small particles (VSSP) from complex of outer membrane proteins of Neisseria meningitides ; d) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23; e) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23, said composition being mixed with or fused to p64K protein of Neisseria meningitides ; f) VEGFR2 polypeptide fragment identified as the amino acid sequence set forth in SEQ ID NO: 23, said composition being mixed with or from complex of outer membrane proteins of Neisseria meningitides ; g) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25; h) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25, said composition being mixed with or fused to p64K protein of Neisseria meningitides ; or i) VEGFR2 polypeptide fragment identified as VEGF-A SEQ ID NO: 25, said composition being mixed with or noncovalently bound to very small particles (VSSP) from comples of outer membrane proteins of Neisseria meningitides ; and optionally further comprising a pharmaceutically accepted adjuvant.